Clareo Health | Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Age
20–66
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The subject was randomized into Study M10-855 and completed through Week 26 in that study.
The subject is receiving one or more antipsychotic medications.
You may not be if
Additional history collected during participation in Study M10-855 provides evidence that, in the investigator's judgement, the subject does not have schizophrenia.
The subject experienced an adverse event or abnormal finding during physical examination, vital signs, laboratory profile, and/or electrocardiogram (ECG) measurements in Study M10-855 that indicates the subject is likely to become medically unstable during the current study.
The subject is currently taking or is expected to be prescribed any excluded medication without the approval of AbbVie medical monitor.
The subject is currently enrolled in, or plans to participate in, another interventional study during the course of this trial.
